July 17th 2012 -- Biofortuna, a UK based molecular diagnostics company specialising in its own proprietary freeze-dried expertise and cryo-preservatives, is launching a new contract Development and Production Service.
Building on the proven design, development and production expertise of Biofortuna this service will be of interest to companies who wish to develop stabilised molecular diagnostics products to gain an additional competitive advantage. The services range from the conversion of a currently available PCR test through to the management of a full development and production project.
The freeze-dried product, including taq polymerase, is not only stable at ambient temperatures for up to 16 months, but has an instantly soluble freeze dried pellet avoiding the need for vortexing or pipette mixing. Biofortuna’s freeze-dried solution results in one step protocols where the end user is only required to add sample DNA prior to amplification and detection.
Dr Simon Douglas, Biofortuna’s CEO said: “We are delighted to be launching this service and allowing companies to access our high level of design and production expertise as well as our proprietary freeze-dried technology. This service will allow companies to create simple stable and long lasting diagnostic kits that will differentiate their products in the market place whilst enhancing speed and reproducibility in laboratory testing.”
He added: “This builds on our current range of CE marked freeze dried stabilised HLA kits which are distributed globally.”
About Biofortuna Ltd
Biofortuna Ltd, the UK-based molecular diagnostics company, specialises in proprietary freeze-dried molecular diagnostics. Biofortuna has a number of freeze-dried molecular diagnostic products distributed and used globally. It is also developing a portfolio of additional tests and offers a development and production service. This aims to provide easy-to-use diagnostics that address complex genotyping issues, whilst increasing laboratory productivity and improving quality in clinical testing and patient care.
Biofortuna's news releases and other information are available on the company's website www.biofortuna.com
Biofortuna Media Contacts
Dr Simon Douglas
Chief Executive Officer